SIGA Secures Canadian Defence Contract for TPOXX, Bolstering International Diversification

What happened

SIGA Technologies announced a contract valued at up to $15 million from the Canadian Department of National Defence to purchase TPOXX. This marks another international order for the company, which has been seeking to reduce reliance on U.S. government contracts. The contract is consistent with SIGA's strategy to expand sales to allied governments and strengthen biodefense stockpiles. While the amount is relatively small compared to total revenue, it demonstrates continued demand for TPOXX outside the United States. This development is a positive signal for SIGA's international diversification efforts, though the core business remains dependent on U.S. procurement.

Implication

The Canadian contract adds up to $15 million in potential revenue, which is incremental but not transformative relative to SIGA's annual revenue of around $139 million. It reinforces the trend of international orders, which have been growing but remain a small portion of total sales. This may help offset some of the concentration risk from U.S. government contracts, but the majority of revenue still comes from BARDA and DoD. The contract also underscores the ongoing demand for TPOXX in biodefense, but investors should remain cautious about the mpox efficacy concerns and competition from Tembexa. Overall, this news is a small positive that slightly improves the diversification story without changing the fundamental risks.

Thesis delta

The new Canadian contract slightly strengthens the international sales component of the thesis, providing evidence of recurring allied demand. However, it does not alter the primary risks: U.S. contract concentration, BARDA's dual-sourcing strategy, and weak mpox efficacy data. The overall thesis remains a high-risk, value-oriented play on biodefense policy, with a slight improvement in the diversification outlook.